MannKind (NASDAQ:MNKD) Shares Gap Up – Should You Buy?

Shares of MannKind Corporation (NASDAQ:MNKD) gapped up prior to trading on Wednesday . The stock had previously closed at $2.86, but opened at $3.44. MannKind shares last traded at $4.0360, with a volume of 13,476,478 shares trading hands.

Key Stories Impacting MannKind

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: MannKind said it is targeting $110 million to $120 million in 2026 FUROSCIX revenue, which suggests management sees continued commercial growth ahead as key regulatory catalysts approach. Article Title
• Positive Sentiment: RBC raised its price target on MannKind to $4.75 from $3.50, indicating some analysts still see upside despite near-term earnings volatility.
• Neutral Sentiment: TipRanks highlighted that MannKind’s earnings call focused on growth initiatives and navigating earnings volatility, reinforcing that the investment case is now being driven more by future execution than the recent quarter. Article Title
• Neutral Sentiment: MannKind’s Q1 earnings presentation and earnings snapshot provided additional detail on results, but did not change the core takeaway that the quarter was softer than expected. Article Title Article Title
• Negative Sentiment: MannKind reported a Q1 loss of $0.05 per share, wider than the expected $0.02 loss, and revenue of $90.17 million came in below consensus, prompting a negative reaction in the stock. Article Title
• Negative Sentiment: Mizuho cut its price target to $7.00 from $8.00, reflecting some caution ahead of upcoming regulatory and commercial milestones. Article Title

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on MNKD. Wells Fargo & Company raised their target price on MannKind from $8.00 to $10.00 and gave the company an “overweight” rating in a research note on Thursday. Royal Bank Of Canada increased their price target on MannKind from $3.50 to $4.75 and gave the company a “sector perform” rating in a report on Thursday. HC Wainwright raised their price objective on MannKind from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday. Wedbush dropped their price objective on MannKind from $10.00 to $8.00 and set an “outperform” rating on the stock in a report on Thursday, March 5th. Finally, Mizuho cut their target price on MannKind from $8.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.84.

MannKind Stock Down 0.8%

The company has a market cap of $1.09 billion, a P/E ratio of -50.28 and a beta of 1.04. The company has a 50 day moving average price of $2.73 and a 200-day moving average price of $4.59.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). The firm had revenue of $90.17 million for the quarter, compared to the consensus estimate of $105.38 million. MannKind had a negative net margin of 6.63% and a negative return on equity of 11.21%. The business’s revenue for the quarter was up 15.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.04 earnings per share. On average, research analysts expect that MannKind Corporation will post -0.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Michael Castagna purchased 100,000 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average price of $2.59 per share, for a total transaction of $259,000.00. Following the completion of the acquisition, the chief executive officer directly owned 2,575,911 shares of the company’s stock, valued at $6,671,609.49. The trade was a 4.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 2.60% of the company’s stock.

Institutional Trading of MannKind

Several institutional investors have recently made changes to their positions in MNKD. JPMorgan Chase & Co. lifted its stake in shares of MannKind by 51.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,047,869 shares of the biopharmaceutical company’s stock valued at $10,997,000 after purchasing an additional 695,852 shares during the last quarter. Deltec Asset Management LLC acquired a new position in MannKind during the third quarter worth $3,885,000. Swiss Life Asset Management Ltd bought a new position in MannKind during the third quarter valued at about $72,000. 180 Wealth Advisors LLC lifted its position in shares of MannKind by 3.0% in the fourth quarter. 180 Wealth Advisors LLC now owns 2,958,944 shares of the biopharmaceutical company’s stock worth $16,777,000 after buying an additional 86,658 shares during the last quarter. Finally, Burkett Financial Services LLC acquired a new stake in shares of MannKind in the fourth quarter worth about $59,000. 49.55% of the stock is currently owned by institutional investors and hedge funds.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).